Agomab Secures U.S. Patent for AGMB-447 Inhaled IPF Therapy, Protection to 2041
Agomab’s AGMB-447 inhaled ALK5 inhibitor received U.S. Patent No. 12,577,230 granting IP protection through at least 2041. The drug, currently in a Phase 1b idiopathic pulmonary fibrosis study, targets lung-restricted TGFβR1 and aims to avoid systemic exposure via rapid plasma hydrolyzation.
1. Patent Grant and Coverage
U.S. Patent No. 12,577,230 was awarded to Agomab, covering the composition of matter for AGMB-447. This protection extends through at least 2041, excluding potential patent term extensions.
2. Mechanism and Design
AGMB-447 is an inhaled, lung-restricted small molecule inhibitor of ALK5 (TGFβR1) designed to concentrate activity in pulmonary tissue. Rapid hydrolysis in plasma minimizes systemic exposure and reduces potential off-target effects.
3. Clinical Development Status
AGMB-447 is currently in a Phase 1b study for idiopathic pulmonary fibrosis, with initial healthy volunteer data reported positively. The IPF patient cohort readout is expected later this year.
4. Strategic Significance
Securing U.S. composition-of-matter patent rights strengthens Agomab’s global IP portfolio for AGMB-447. This milestone supports the company’s goal of delivering a novel inhaled anti-fibrotic therapy to address high unmet need in IPF.